The CHMP expressed positive opinions about the drug as use as a first line treatment for patients with lung cancer. The daily, orally administered drug is already used as a second line treatment.
Roche’s head of global product development, Hal Barron, has said that the positive feedback “is an important step to bringing a personalised medicine option to people with lung cancer.” The use of the drug as a first line treatment is supported by two phase III trials which indicated Tarceva increased progression free survival compared to chemotherapy. The European Medicines Agency is expected to approve the drug in around three months.
Looking for a job in the pharmaceutical industry? Start by clicking here, now